Health technology assessment (HTA) and economic evaluation: efficiency or fairness first [0.03%]
卫生技术评估（HTA）和经济评价：效率还是公平优先
Jeff Richardson,Michael Schlander
Jeff Richardson
The economic evaluation which supports Health Technology Assessment (HTA) should inform policy makers of the value to society conferred by a given allocation of resources. However, neither the theory nor practise of economic evaluation sati...
Szymon Jarosławski,Mondher Toumi
Szymon Jarosławski
Non-profit drug research and development (R&D) has the potential to deliver innovative treatments at affordable prices. Using the case study methodology, we discuss some ethical and economic issues, including the possible impact of non-prof...
Patient-reported outcome claims in European and United States orphan drug approvals [0.03%]
欧盟和美国罕见病药物审批中的患者报告结果的主张
Szymon Jarosławski,Pascal Auquier,Borislav Borissov et al.
Szymon Jarosławski et al.
Purpose: We aimed to evaluate the rate of usage and the kind of patient-reported outcome (PRO) claims in orphan drug approvals from the European Medicines Agency (EMA) dated between 1/1/2012 and 31/12/2016 and to compare them to those from ...
Budget impact of antimicrobial wound dressings in the treatment of venous leg ulcers in the German outpatient care sector: a budget impact analysis [0.03%]
德国门诊护理领域抗微生物伤口敷料治疗静脉腿溃疡的成本影响分析：预算影响力分析
Maria Gueltzow,Poroshat Khalilpour,Katharina Kolbe et al.
Maria Gueltzow et al.
Background: Hard-to-heal wounds are associated with high treatment costs and, in Germany, are mostly treated in the outpatient care sector. Wound dressings are the main cost-drivers in venous leg ulcer (VLU) care which prescription is budge...
The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson's disease [0.03%]
基于NICE和ICER的成本效用及预算影响评价方法的新型基因治疗药物在英国和美国的价格与可及性问题分析——以帕金森病为例
Jesper Jørgensen,Spiros Servos,Panos Kefalas
Jesper Jørgensen
Background: NICE in England, and ICER in the US both use cost-utility analyses (CUA) and budget impact analyses (BIA) to assess value for money and affordability, however the thresholds used differ greatly. Objective: To perform a cross-cou...
Health related quality of life in patients having schizophrenia negative symptoms - a systematic review [0.03%]
系统综述：精神分裂症阴性症状患者的健康相关生活质量研究
Chiraz Azaiez,Aurélie Millier,Christophe Lançon et al.
Chiraz Azaiez et al.
Background: Schizophrenia negative symptoms (SNS) contribute substantially to poor functional outcomes, loss in productivity and poor quality of life. It is unclear which instruments may be used for assessing quality of life in patients wit...
Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy [0.03%]
假设性CAR-T细胞治疗基于绩效的管理准入协议的实施成本研究
Panos Kefalas,Omar Ali,Jesper Jørgensen et al.
Panos Kefalas et al.
Background: Market access stakeholders consider the adoption of Managed Entry Agreements (MEAs), however a clearly described methodology to quantify their implementation burden is not available in the public domain. Objective: To quantify t...
Junwen Zhou,Aurélie Millier,Mondher Toumi
Junwen Zhou
Background: Economic models are broadly used in the economic evaluation of antipsychotics in schizophrenia. Our objective was to summarize the structure of these models. Methods: Model-based economic evaluations of antipsychotics in schizop...
Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK [0.03%]
英国用于静脉血栓栓塞性疾病治疗和二级预防的 edoxaban 与华法林的成本效益分析
Emilie Clay,Aurélien Jamotte,Peter Verhamme et al.
Emilie Clay et al.
Background: Venous thromboembolism (VTE), which includes pulmonary embolism (PE) and deep vein thrombosis (DVT), is the third most common acute cardiovascular disease and represents an important burden for patients and payers. Objective: Th...
Approaches to manage 'affordability' of high budget impact medicines in key EU countries [0.03%]
欧盟主要国家高预算影响药物“可负担性”的管理方法论分析
Mathias Flume,Marc Bardou,Stefano Capri et al.
Mathias Flume et al.
Background: The launch of hepatitis C (HCV) drugs such as sofosbuvir or ledipasvir has fostered the question of affordability of novel high budget impact therapies even in countries with high domestic product. European countries have develo...